One-Time gene therapy could free hemophilia patients from frequent infusions
NCT ID NCT06111638
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests a one-time gene therapy called BBM-H803 for adults with severe hemophilia A. The treatment uses a harmless virus to deliver a working gene to the liver, so the body can produce its own clotting factor VIII. The study involves 55 participants and will check safety, liver function, and how well it reduces bleeding episodes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BBM-H803 (a gene therapy using a harmless virus to deliver a working factor VIII gene to the liver)
What this could lead to
If successful, this could allow people with severe hemophilia A to produce their own clotting factor, reducing or stopping the need for regular factor infusions.
What could go wrong
This is an early-to-mid stage trial with only 55 participants. Gene therapy may not work for everyone, and there are risks like liver inflammation or an immune reaction to the virus.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Guizhou Medical University
RECRUITINGGuiyang, Guizhou, 550001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100005, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sichuan Provincial People's Hospital
RECRUITINGChengde, Sichuan, 610031, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Southern Hospital, Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510515, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Affiliated Hospital of Northwest University Xi'an No.3 Hospital
RECRUITINGXi’an, Shanxi, 710000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Affiliated Hospital of Kunming Medical University
RECRUITINGKunming, Yunnan, 650032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Wuhan Union Hospital Affiliated to Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xiangya Hospital Central South University
RECRUITINGChangsha, Hunan, 410008, China
Contact Phone: •••-•••-•••• Email: •••••@•••••